What does ibogaine feel like? Based on how clinics describe their own protocols and on the few clinical studies that report effects, it is a long and tiring experience: unsteadiness and often nausea at the start, an inward, dream-like state in which many people lie still with their eyes closed, and a day or more of exhaustion afterward. Clinics describe the length differently, from several hours of intense experience (Beond) to about 36 hours for the dose and its effects (IbogaQuest), so any single figure is one provider's wording. Ibogaine also carries a documented risk to heart rhythm, which is why the sequence below is built around monitoring. This page sets out the typical order of events as providers and published research describe it, and where the evidence stops. It contains no personal accounts, it is not medical advice, and it cannot tell you what the experience would be like for you.
The sequence clinics describe
These are provider statements about their own programs, not measurements, and each clinic does it differently.
Before the dose. MindScape Retreat lists fasting for 6 to 8 hours beforehand, with an IV line and cardiac telemetry started when the main dose is given. The Iboga Wellness Institute describes no solid food for 8 to 12 hours and no liquids for 4 to 6 hours, with IV hydration. Some clinics give smaller doses first: MindScape lists twice-daily sublingual booster doses on days 1 to 3, and Ambio and Beond both mention additional doses when clinically recommended.
Onset. MindScape places unsteadiness (ataxia), possible nausea, buzzing or music-like sounds and sensitivity to light and sound in roughly the first four hours. The Iboga Wellness Institute's FAQ lists nausea, ataxia and sensitivity to light and sound during the peak hours and says the team manages them. Beond lists unsteadiness, nausea and vomiting as common.
The main phase. Ambio calls the experience deeply internal and often a dream-like, introspective journey, and says most people lie still with their eyes closed. The Iboga Wellness Institute says you are not unconscious but in a deeply inward state, and that many people see vivid internal visions. MindScape gives a visionary phase of typically 4 to 8 hours, states that this phase is not universal, and says ibogaine is not anesthesia. Beond adds that some people find the experience intense, confronting or emotionally difficult at points, and the Institute says rescue medication, including a benzodiazepine, is available.
Afterward. MindScape describes deep fatigue, little appetite and sleep that can be disrupted for a few nights. The Institute says sleep is often difficult for 24 to 48 hours and that low mood, fatigue or emotional flatness on the following day typically lasts 24 to 72 hours. Ambio describes the day after as often one of physical exhaustion and emotional processing. The Institute recommends staying at least 24 hours after the active phase before flying.
How long clinics say it lasts
| Clinic | Duration as stated |
|---|---|
| Ambio | Flood dose in a monitored session lasting 12 to 24 hours |
| MindScape Retreat | Acute experience 18 to 24 hours from the dose; visionary phase typically 4 to 8 hours |
| Iboga Wellness Institute | Its FAQ says the acute experience lasts about 12 hours and that active monitoring runs about 24 to 36 hours, with 24 to 48 hours of close monitoring after the session; one FAQ answer also says the experience typically lasts 24 to 36 hours, and its treatments page says treatment sessions typically last 24 to 36 hours |
| IbogaQuest | Flood dose lasting approximately 36 hours |
| Beond | Intense experience usually several hours, then a reflective period of a day or more |
The numbers differ because the clinics measure different things and use different protocols, and the Iboga Wellness Institute gives both an experience figure and a monitoring figure, so treat any single number as one provider's description. IbogaQuest also says ibogaine affects each person differently.
How monitoring fits in
IbogaQuest states that vital signs are checked every hour for the first 12 hours after the full dose, that a physician, nurse, paramedics and an ambulance are on site on medicine days, and that guests stay under the team's care for at least 72 hours after the first dose, according to its safety page. The Institute and Beond each describe a repeat ECG within 24 hours.
What published studies report
In a 2022 Dutch observational study of 14 people with opioid use disorder, who were first switched to morphine and then each given a single dose of ibogaine and monitored for at least 24 hours, all had severe but temporary ataxia and could not walk without support. Half reached a QTc interval above 500 milliseconds, a marker of heart-rhythm risk, and the authors reported no torsades de pointes. Withdrawal and psychomimetic effects were mostly well tolerated after that switch to morphine, so the result does not show how ibogaine alone would affect withdrawal. Source: Knuijver and colleagues, 2022
A 2024 open-label study of 30 veterans, given ibogaine with magnesium, reported no unexpected or serious adverse events. It had no control group, and three of its authors disclose being shareholders in Ambio Life Sciences, which offers ibogaine treatment and is one of the clinics quoted on this page; one of them also founded a company that sources ibogaine precursors and converts them into ibogaine. Source: Cherian and colleagues, 2024 A systematic review of adverse events found that acute events were mainly cardiac, with QTc prolongation the most common, along with gastrointestinal and neurological changes, and that most reports were case reports or uncontrolled studies. Source: Ona and colleagues, 2022
What is uncertain
A 2026 review in Addiction describes a rare but clinically significant cardiac risk, including in people without known heart conditions, and recommends medical supervision with close cardiac monitoring. Source: Addiction, 2026 Another 2026 review found that most positive results come from uncontrolled studies at high risk of bias and that current evidence is insufficient to support clinical use. Source: Kervadec and colleagues, 2026 In the United States, ibogaine is listed among the Schedule I hallucinogenic substances in federal regulation. Source: 21 CFR 1308.11 This page does not assess how Mexican law applies to a particular clinic.
Questions worth asking any clinic
- Is treatment a single dose or several, and how long will I be monitored afterward?
- Who is at the bedside during the session, and who responds if the heart rhythm changes?
- What medicine is available for nausea or severe anxiety?
- How long should I stay before flying home, and what follow-up is available?
How this page was made
We read each clinic's public page and each study's PubMed record on 30 October 2026 and recorded only what they state. We did not contact any clinic, receive a fee or referral payment, or verify any clinic's claims. The studies were read at abstract level, and we left out personal accounts and clinic outcome statistics. Talk with a qualified physician about your own health, including any heart condition or medication you take.
Evidence and Scope
Sources and Limits
These sources explain general treatment settings and questions. Check the services, professionals and arrangements of each program directly.
- MindScape Retreat, Cozumel (what to expect page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used. This provider also publishes a referral program; none is used here. Its percentage of patients reporting visions is not used.Observed
- IbogaQuest, TepoztlanProvider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used.Observed
- IbogaQuest, Tepoztlan (safety and screening page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used.Observed
- Iboga Wellness Institute (FAQ page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used. Only the first 100,000 of 148,347 characters were read. The page gives both about 12 hours and 24 to 36 hours for the experience; its own fatality and cardiac-event figures are not used.Observed
- Iboga Wellness Institute (treatments page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used. Only the first 100,000 of 126,662 characters were read.Observed
- Ambio Life Sciences (FAQ page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used.Observed
- Beond Ibogaine (FAQ page)Provider's own marketing or FAQ page; describes the clinic's stated protocol and expected effects, not a measurement or an independent finding, and not verified. Protocols change; read by plain HTTP fetch, no provider contact. Outcome statistics and personal accounts on the page are not used. The page cites an unreviewed 2026 preprint on deaths; that figure is not used.Observed
- Addiction (Abingdon, England) 117(1):118-128 (2022), Knuijver et al.; PubMed PMID 33620733The abstract was read on PubMed on 2026-10-31 and matches the Europe PMC record read on 2026-10-30. Small descriptive open-label study (14 people, single dose, no control group); the full text was not read.Observed
- Nature Medicine (2024), Cherian et al.; PubMed PMID 38182784Abstract and disclosures read on PubMed; full text not read. Open-label, no control group, 30 male special-operations veterans with mostly mild brain injury; the PubMed disclosures state that three authors are shareholders in Ambio Life Sciences (which offers ibogaine treatment and is also a clinic source on this page) and that one founded a company that sources ibogaine precursors; some authors are also named on patent applications.Observed
- Psychopharmacology (2022), Ona et al., adverse events of ibogaine, updated systematic review 2015-2020; PubMed PMID 34406452Abstract read on PubMed; full text not read. The abstract reports 18 included studies, mostly case reports or uncontrolled, so causation cannot be established; it gives no case counts.Observed
- Addiction (Abingdon, England) 121(6):1616-1621, review by T. M. Brunt; PubMed PMID 41560340, DOI 10.1111/add.70319Abstract read on PubMed; full text not read. Describes cardiac risk and the author's recommendation; no individual medical advice and no assessment of any clinic. No qualified clinical review of this article is recorded.Observed
- Journal of Clinical Psychopharmacology (2026), Kervadec et al., Thirty Years of Ibogaine Research; PubMed PMID 42228481Abstract read on PubMed; full text not read. Narrative review of human studies from 1990 to February 2025; summarises efficacy and safety evidence, not any clinic's practice.Observed
- Electronic Code of Federal Regulations, 21 CFR 1308.11 (DEA Schedule I)Text read on 2026-10-30 through the Cornell LII mirror because eCFR redirected automated access; confirm against eCFR before release. Says nothing about Mexican law or about any clinic.Observed
